Juji Dai
Impact in
- Cancer Research top 10%
- Cancer, Lipids, and Metabolism
- Cancer-related molecular mechanisms research
- Cancer, Hypoxia, and Metabolism
- MicroRNA in disease regulation
-
- Ferroptosis and cancer prognosis
Papers in
-
- RNA modifications and cancer 4
- Phosphodiesterase function and regulation 2
- Wnt/β-catenin signaling in development and cancer 2
- Protein Kinase Regulation and GTPase Signaling 2
-
- MicroRNA in disease regulation 2
- Cancer, Hypoxia, and Metabolism 2
- Co-authors
- Lechi Ye (4 shared papers)Wei Cen (2 shared papers)Jiawen Yang (1 shared paper)Jiajie Mo (1 shared paper)Lei Jiang (1 shared paper)Bicheng Chen (2 shared papers)Yongyu Bai (3 shared papers)Liting Lu (7 shared papers)
In The Last Decade
Juji Dai
19 papers receiving 684 citations
Juji Dai's Hit Papers
Peers
Comparison fields: 5 of 75
- Cancer Research 199
- Pulmonary and Respiratory Medicine 204
- Molecular Biology 348
- Hepatology 35
- Oncology 102
Countries citing papers authored by Juji Dai
This map shows the geographic impact of Juji Dai's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Juji Dai with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Juji Dai more than expected).
Fields of papers citing papers by Juji Dai
This network shows the impact of papers produced by Juji Dai. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Juji Dai. The network helps show where Juji Dai may publish in the future.
Co-authors
The 25 scholars most cited alongside Juji Dai, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Cetuximab promotes RSL3-induced ferroptosis by suppressing the Nrf2/HO-1 signalling pathway in KRAS mutant colorectal cancer Hit paper breakdown → | 2021 | 238 |
| 2 | 2020 | 119 | |
| 3 | 2015 | 82 | |
| 4 | 2016 | 61 | |
| 5 | 2017 | 52 | |
| 6 | 2015 | 35 | |
| 7 | 2016 | 17 | |
| 8 | 2015 | 13 | |
| 9 | 2018 | 12 | |
| 10 | 2022 | 12 | |
| 11 | 2022 | 11 | |
| 12 | 2022 | 9 | |
| 13 | 2022 | 7 | |
| 14 | 2023 | 5 | |
| 15 | 2019 | 4 | |
| 16 | Primary anorectal malignant melanoma: a case report. | 2020 | 4 |
| 17 | 2022 | 3 | |
| 18 | 2023 | 1 | |
| 19 | 2025 | 1 |
About Juji Dai
Juji Dai is a scholar working on Molecular Biology, Cancer Research, Pulmonary and Respiratory Medicine, Oncology and Immunology, having authored 19 papers that have together received 686 indexed citations. Recurring topics across this work include RNA modifications and cancer (4 papers), Ferroptosis and cancer prognosis (2 papers), Phosphodiesterase function and regulation (2 papers), Wnt/β-catenin signaling in development and cancer (2 papers), Protein Kinase Regulation and GTPase Signaling (2 papers), MicroRNA in disease regulation (2 papers), Cancer, Hypoxia, and Metabolism (2 papers) and Sarcoma Diagnosis and Treatment (1 paper). The work is most often cited by research in Cancer Research (199 citations), Pulmonary and Respiratory Medicine (204 citations), Molecular Biology (348 citations), Hepatology (35 citations) and Oncology (102 citations). Juji Dai has collaborated with scholars based in China and Hong Kong. Frequent co-authors include Lechi Ye, Wei Cen, Jiawen Yang, Jiajie Mo, Lei Jiang, Bicheng Chen, Yongyu Bai, Liting Lu, Xincheng Lu and Mengtao Zhou. Their work appears in journals such as Cell Death and Disease, Biochemical and Biophysical Research Communications, Molecular and Cellular Biochemistry, Cancer Medicine and Frontiers in Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.